Distinguished in Graft Versus Host Disease (GvHD)

Denis-claude C. Roy

Montreal, QC, CA 
Distinguished in Graft Versus Host Disease (GvHD)
Montreal, QC, CA 
OverviewLocationsClinical Research

Overview

Denis-claude Roy practices in Montreal, Canada. Roy is rated as a Distinguished expert by MediFind in the treatment of Graft Versus Host Disease (GvHD). Their top areas of expertise are Graft Versus Host Disease (GvHD), Febrile Neutropenia, Chronic Graft Versus Host Disease (cGvHD), Bone Marrow Transplant, and Transcatheter Aortic Valve Replacement (TAVR).

Their clinical research consists of co-authoring 46 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 12 articles in the study of Graft Versus Host Disease (GvHD).

Locations

Montreal, QC H1T2M4, Canada
Other Locations
Canada
Quebec, QC, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase I-II Open-label Study of UM171 Expanded Cord Blood in a Fed-batch Culture System (UFCB-001) in Patients Who Need an Allogeneic Hematopoietic Stem Cell Transplant But Lack a Suitable Donor
A Phase I-II Open-label Study of UM171 Expanded Cord Blood in a Fed-batch Culture System (UFCB-001) in Patients Who Need an Allogeneic Hematopoietic Stem Cell Transplant But Lack a Suitable Donor
Enrollment Status: Completed
Publish Date: August 05, 2019
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Anti-minor Histocompatibility Complex (MiHA) Donor T-lymphocytes Expanded ex Vivo, in Patients With a Hematologic Malignancy, With Molecular or Clinical Relapse After Hematopoietic Stem Cell Transplantation From a Matched Donor
An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Anti-minor Histocompatibility Complex (MiHA) Donor T-lymphocytes Expanded ex Vivo, in Patients With a Hematologic Malignancy, With Molecular or Clinical Relapse After Hematopoietic Stem Cell Transplantation From a Matched Donor
Enrollment Status: Unknown
Publish Date: December 06, 2017
Intervention Type: Biological
Study Drug: GLIDE
Study Phase: Phase 1/Phase 2
The IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing CABG With Left Ventricular Dysfunction: the IMPACT-CABG Study
The IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing CABG With Left Ventricular Dysfunction: the IMPACT-CABG Study
Enrollment Status: Completed
Publish Date: October 18, 2017
Intervention Type: Procedure
Study Phase: Not Applicable
View 2 Less Clinical Trials

46 Total Publications

Allogeneic Hematopoietic Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center.
Allogeneic Hematopoietic Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center.
Journal: Current oncology (Toronto, Ont.)
Published: March 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Roy's expertise for a condition
ConditionClose
    View All 18 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile